Keyphrases
Japan
100%
Invasive Pneumococcal Disease
100%
Pneumococcal Disease
100%
Cost-effectiveness Analysis
100%
Pneumococcal Conjugate Vaccine
100%
PPSV23
75%
Quality-adjusted Life Years
75%
Disease Case
50%
PCV20
50%
Payer Perspective
50%
High-risk Adults
50%
Disease-associated
25%
Cost Savings
25%
Cost-effectiveness
25%
Older Adults
25%
Disease Incidence
25%
23-valent Pneumococcal Polysaccharide Vaccine
25%
Incremental Cost-effectiveness Ratio
25%
Societal Perspective
25%
Perspective Analysis
25%
Lifetime Cost
25%
Markov Model
25%
National Immunization Program
25%
Cost-effectiveness Threshold
25%
Healthcare Payer
25%
20-valent Pneumococcal Conjugate Vaccine
25%
Medicine and Dentistry
Disease
100%
Cost-Effectiveness Analysis
100%
Pneumococcal Infection
100%
Pneumococcus Vaccine
100%
Health Care Cost
75%
Quality Adjusted Life Year
75%
Outpatient
25%
Morbidity
25%
Lifespan
25%
Base
25%
Research Design
25%
Pneumococcus Polysaccharide
25%
Polysaccharide Vaccine
25%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Pneumococcal Infection
100%
Pneumococcus Vaccine
100%
Morbidity
25%
Base
25%
Polysaccharide Vaccine
25%
Pneumococcus Polysaccharide
25%